# uniQure (stock symbol: QURE) Logo in transparent PNG and SVG formats

## uniQure Logo large

### uniQure Logo large Download PNG (16.11 KB)

![uniQure Logo large Download PNG (16.11 KB)](/img/orig/QURE_BIG-4824e4e7.png)

### uniQure Logo large Download SVG (1.97 KB)

![uniQure Logo large Download SVG (1.97 KB)](/img/orig/QURE_BIG-9568b554.svg)

## uniQure Logo icon format

### uniQure Logo icon format Download PNG (27.37 KB)

![uniQure Logo icon format Download PNG (27.37 KB)](/img/orig/QURE-c3103acb.png)

### uniQure Logo icon format Download SVG (861 Bytes)

![uniQure Logo icon format Download SVG (861 Bytes)](/img/orig/QURE-da3c7d44.svg)

## About uniQure

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

1. Website domain: uniqure.com
2. Employees: 463
3. Marketcap: $0.91 Billion USD


## Categories
- [x] ðŸ‡³ðŸ‡± Netherland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
- [x] ðŸ§¬ Genomics
- [x] ðŸ§¬ Gene therapy
